BioMed Research International / 2015 / Article / Tab 2

Research Article

Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study

Table 2

Actionable biomarkers (i.e., biomarkers predictive of response to specific therapies) identified by immunohistochemistry and microarray analysis.

TargetNumber of patients out of evaluable patients ()Frequency, %

 Negative/low TS27/2896.4
 Negative/low RRM123/2688.5
 High TOPO122/2878.6
 Negative/low ERCC119/2673.1
 High EGFR3/560.0
 Positive TLE33/650.0
 High SPARC112/3040.0
 Negative/low MGMT11/2937.9
 High PDGFR5/1729.4
 High TOPO2A5/2520.0
 High c-Kit4/2416.7
 Positive PgR2/277.4
 Positive HER20/300.0
 Positive ER0/270.0
 Positive AR0/270.0
Microarray analysis
TOP2A overexpression13/1776.5
HIF1A overexpression9/1752.9
PDGFRB overexpression9/1752.9
SRC overexpression8/1747.1
TOP2B overexpression7/1741.2
VDR overexpression7/1741.2
RRM2B underexpression6/1735.3
ASNS underexpression5/1729.4
BRCA1 underexpression5/1729.4
BRCA2 underexpression5/1729.4
KIT overexpression5/1729.4
PDGFRA overexpression5/1729.4
ERCC1 underexpression4/1723.5
MGMT underexpression3/1717.6

SPARC levels were considered high if either of the analyses (using monoclonal or polyclonal antibodies) demonstrated high SPARC expression levels.
5-FU: 5- fluorouracil; AR: androgen receptor; ASNS: asparagine synthetase; BRCA 1/2: breast cancer 1/2, early onset; EGFR: epidermal growth factor receptor; ER: estrogen receptor; ERCC1: excision repair cross complementation 1; FISH: fluorescent in situ hybridization; HER2: human epidermal growth factor receptor 2; HIF1A: hypoxia-inducible factor 1-alpha; IHC: immunohistochemistry; MGMT: O-6-methylguanine-DNA methyltransferase; PDGFR: platelet-derived growth factor receptor; PgR: progesterone receptor; RRM1: ribonucleotide reductase M1 subunit; RRM2B: ribonucleotide reductase M2 B; SPARC: secreted protein acidic, rich in cysteine; TLE3: transducin-like enhancer of split 3; TOP2B: topoisomerase II beta; TOPO1: topoisomerase 1; TOPO2A: topoisomerase IIA; TS: thymidylate synthase; VDR: vitamin D receptor.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.